Cipher Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA17253X1050
CAD
14.72
-0.08 (-0.54%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

22.43 k

Shareholding (Sep 2024)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 25.10%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64

 
3

With a growth in Net Profit of 116.61%, the company declared Very Positive results in Jun 25

4

With ROE of 11.37%, it has a fair valuation with a 2.70 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 371 Million (Small Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.13

stock-summary
Return on Equity

11.37%

stock-summary
Price to Book

2.48

Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2025)
Net Profit:
8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.01%
0%
-7.01%
6 Months
18.33%
0%
18.33%
1 Year
-6.6%
0%
-6.6%
2 Years
135.9%
0%
135.9%
3 Years
317.0%
0%
317.0%
4 Years
760.82%
0%
760.82%
5 Years
1535.56%
0%
1535.56%

Cipher Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.30%
EBIT Growth (5y)
-11.25%
EBIT to Interest (avg)
12.64
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
0.27
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
37.30%
ROE (avg)
25.10%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
2.49
EV to EBIT
39.27
EV to EBITDA
19.73
EV to Capital Employed
2.32
EV to Sales
5.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.91%
ROE (Latest)
11.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.56% vs 4.24% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 115.79% vs -19.15% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.50",
          "val2": "17.20",
          "chgp": "7.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.40",
          "val2": "6.00",
          "chgp": "56.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.70",
          "chgp": "-28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8.20",
          "val2": "3.80",
          "chgp": "115.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "373.00%",
          "val2": "195.20%",
          "chgp": "17.78%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 59.79% vs 6.32% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -42.55% vs -20.75% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "45.70",
          "val2": "28.60",
          "chgp": "59.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.50",
          "val2": "15.20",
          "chgp": "-17.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "15.80",
          "val2": "27.50",
          "chgp": "-42.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.90%",
          "val2": "474.10%",
          "chgp": "-32.02%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
18.50
17.20
7.56%
Operating Profit (PBDIT) excl Other Income
9.40
6.00
56.67%
Interest
0.50
0.70
-28.57%
Exceptional Items
0.00
0.00
Consolidate Net Profit
8.20
3.80
115.79%
Operating Profit Margin (Excl OI)
373.00%
195.20%
17.78%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 7.56% vs 4.24% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 115.79% vs -19.15% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
45.70
28.60
59.79%
Operating Profit (PBDIT) excl Other Income
12.50
15.20
-17.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
15.80
27.50
-42.55%
Operating Profit Margin (Excl OI)
153.90%
474.10%
-32.02%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 59.79% vs 6.32% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -42.55% vs -20.75% in Dec 2023

stock-summaryCompany CV
About Cipher Pharmaceuticals, Inc. stock-summary
stock-summary
Cipher Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Company Coordinates stock-summary
Company Details
209 Oak Park Blvd, Suite 501 , OAKVILLE ON : L6H 0M2
stock-summary
Tel: 1 905 60258401 416 5199442
stock-summary
Registrar Details